ATR icon

AptarGroup

Positive
Neutral
Negative
Sentiment 3-Months
Positive
Neutral 57.9%
Negative

Neutral
Business Wire
6 days ago
Aptar Announces 2026 Quarterly Conference Call Dates
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Announces 2026 Quarterly Conference Call Dates.
Aptar Announces 2026 Quarterly Conference Call Dates
Neutral
Business Wire
8 days ago
Aptar to Present at 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar to Present at 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026.
Aptar to Present at 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026
Neutral
Business Wire
27 days ago
Aptar's Bidose Nasal System Delivers CARDAMYST™ (etripamil), the First and Only Self-Administered FDA-Approved Nasal Spray for Paroxysmal Supraventricular Tachycardia (PSVT)
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Group, Inc. (NYSE: ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that its Bidose (BDS) Liquid Nasal Spray System is the mechanism for delivering the newly approved CARDAMYST™ (etripamil) Nasal Spray. CARDAMYST received approval by the U.S. Food and Drug Administration (FDA) for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhyt.
Aptar's Bidose Nasal System Delivers CARDAMYST™ (etripamil), the First and Only Self-Administered FDA-Approved Nasal Spray for Paroxysmal Supraventricular Tachycardia (PSVT)
Neutral
Business Wire
1 month ago
Aptar Named One of America's Most Responsible Companies by Newsweek for the Seventh Consecutive Year
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Named One of America's Most Responsible Companies by Newsweek for the Seventh Consecutive Year.
Aptar Named One of America's Most Responsible Companies by Newsweek for the Seventh Consecutive Year
Neutral
Zacks Investment Research
1 month ago
Is the Options Market Predicting a Spike in AptarGroup Stock?
Investors need to pay close attention to ATR stock based on the movements in the options market lately.
Is the Options Market Predicting a Spike in AptarGroup Stock?
Positive
Benzinga
1 month ago
Aptar Strengthens Latin America Footprint With Sommaplast Buy
On Monday, AptarGroup, Inc. (NYSE: ATR) acquired Sommaplast, a specialized provider of oral dosing pharma packaging solutions, such as closures, droppers, dispensers, and dosing cups, based in Brazil.
Aptar Strengthens Latin America Footprint With Sommaplast Buy
Negative
Seeking Alpha
1 month ago
Touchstone Mid Cap Fund Q3 2025 Portfolio Review
The Touchstone Mid Cap Fund (Class A Shares, Load Waived) underperformed its benchmark, the Russell MidCap® Index, for the quarter ended September 30, 2025. Among the largest contributors to Fund performance were Somnigroup International, Inc. (Consumer Discretionary sector), Armstrong World Industries, Inc. (Industrials sector), and NewMarket Corporation (Materials sector). Among the largest detractors from Fund performance were Fidelity National Information Services, Inc. (Financials sector), Allison Transmission Holdings, Inc. (Industrials sector), and AptarGroup, Inc. (Materials sector).
Touchstone Mid Cap Fund Q3 2025 Portfolio Review
Neutral
Seeking Alpha
1 month ago
AptarGroup, Inc. (ATR) Presents at Jefferies London Healthcare Conference 2025 Transcript
AptarGroup, Inc. ( ATR ) Jefferies London Healthcare Conference 2025 November 19, 2025 7:00 AM EST Company Participants Stephan Tanda - President, CEO & Executive Director Gael Touya - President of Aptar Pharma Vanessa Kanu - Executive VP & CFO Conference Call Participants Daniel Rizzo - Jefferies LLC, Research Division Presentation Daniel Rizzo Jefferies LLC, Research Division Good afternoon. I am Dan Rizzo with Jefferies Equity Research.
AptarGroup, Inc. (ATR) Presents at Jefferies London Healthcare Conference 2025 Transcript
Neutral
Business Wire
2 months ago
Aptar to Present at Jefferies Global Healthcare Conference on November 19, 2025
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar to Present at Jefferies Global Healthcare Conference on November 19, 2025.
Aptar to Present at Jefferies Global Healthcare Conference on November 19, 2025
Negative
Seeking Alpha
2 months ago
AptarGroup: Pharma Setback Creates Long-Term Opportunities
AptarGroup's shares have dropped over 25% from summer highs due to slower growth, especially in high-margin pharma emergency solutions. ATR's valuation has compressed from 26x to 20x earnings, reflecting concerns about flat growth and a soft outlook for 2026. Pharma remains the most profitable segment, but headwinds in emergency-use delivery systems are expected to impact revenues next year.
AptarGroup: Pharma Setback Creates Long-Term Opportunities